Introduced:
Jun 6, 2025
Policy Area:
Health
Congress.gov:
Bill Statistics
4
Actions
11
Cosponsors
0
Summaries
1
Subjects
1
Text Versions
Yes
Full Text
AI Summary
AI Summary
No AI Summary Available
Click the button above to generate an AI-powered summary of this bill using Claude.
The summary will analyze the bill's key provisions, impact, and implementation details.
Error generating summary
Latest Action
Jun 6, 2025
Referred to the House Committee on Energy and Commerce.
Actions (4)
Referred to the House Committee on Energy and Commerce.
Type: IntroReferral
| Source: House floor actions
| Code: H11100
Jun 6, 2025
Sponsor introductory remarks on measure. (CR H2516)
Type: IntroReferral
| Source: Library of Congress
| Code: B00100
Jun 6, 2025
Introduced in House
Type: IntroReferral
| Source: Library of Congress
| Code: Intro-H
Jun 6, 2025
Introduced in House
Type: IntroReferral
| Source: Library of Congress
| Code: 1000
Jun 6, 2025
Subjects (1)
Health
(Policy Area)
Cosponsors (7 of 11)
(D-KS)
Aug 15, 2025
Aug 15, 2025
(D-MN)
Jun 23, 2025
Jun 23, 2025
(R-NE)
Jun 6, 2025
Jun 6, 2025
(R-VA)
Jun 6, 2025
Jun 6, 2025
(R-PA)
Jun 6, 2025
Jun 6, 2025
(R-NY)
Jun 6, 2025
Jun 6, 2025
(D-CA)
Jun 6, 2025
Jun 6, 2025
Showing latest 7 cosponsors
Full Bill Text
Length: 2,523 characters
Version: Introduced in House
Version Date: Jun 6, 2025
Last Updated: Nov 15, 2025 2:30 AM
[Congressional Bills 119th Congress]
[From the U.S. Government Publishing Office]
[H.R. 3821 Introduced in House
(IH) ]
<DOC>
119th CONGRESS
1st Session
H. R. 3821
To amend the Federal Food, Drug, and Cosmetic Act to require the label
of a drug intended for human use to identify each ingredient in such
drug that is, or is derived directly or indirectly from, a major food
allergen or a gluten-containing grain, and for other purposes.
_______________________________________________________________________
IN THE HOUSE OF REPRESENTATIVES
June 6, 2025
Ms. Morrison (for herself, Mr. Lawler, Ms. Matsui, Mr. Cline, Mr.
Fitzpatrick, and Mr. Bacon) introduced the following bill; which was
referred to the Committee on Energy and Commerce
_______________________________________________________________________
A BILL
To amend the Federal Food, Drug, and Cosmetic Act to require the label
of a drug intended for human use to identify each ingredient in such
drug that is, or is derived directly or indirectly from, a major food
allergen or a gluten-containing grain, and for other purposes.
Be it enacted by the Senate and House of Representatives of the
United States of America in Congress assembled,
[From the U.S. Government Publishing Office]
[H.R. 3821 Introduced in House
(IH) ]
<DOC>
119th CONGRESS
1st Session
H. R. 3821
To amend the Federal Food, Drug, and Cosmetic Act to require the label
of a drug intended for human use to identify each ingredient in such
drug that is, or is derived directly or indirectly from, a major food
allergen or a gluten-containing grain, and for other purposes.
_______________________________________________________________________
IN THE HOUSE OF REPRESENTATIVES
June 6, 2025
Ms. Morrison (for herself, Mr. Lawler, Ms. Matsui, Mr. Cline, Mr.
Fitzpatrick, and Mr. Bacon) introduced the following bill; which was
referred to the Committee on Energy and Commerce
_______________________________________________________________________
A BILL
To amend the Federal Food, Drug, and Cosmetic Act to require the label
of a drug intended for human use to identify each ingredient in such
drug that is, or is derived directly or indirectly from, a major food
allergen or a gluten-containing grain, and for other purposes.
Be it enacted by the Senate and House of Representatives of the
United States of America in Congress assembled,
SECTION 1.
This Act may be cited as the ``Allergen Disclosure In Non-food
Articles Act'' or the ``ADINA Act''.
SEC. 2.
ALLERGEN OR IS MADE FROM A GLUTEN-CONTAINING GRAIN.
(a) Misbranding.--
(a) Misbranding.--
Section 502 of the Federal Food, Drug, and
Cosmetic Act (21 U.
Cosmetic Act (21 U.S.C. 352) is amended by adding at the end the
following:
``
(hh) If it is a drug--
``
(1) that is intended for human use;
``
(2) that contains an ingredient that is, or is derived
directly or indirectly from--
``
(A) a major food allergen; or
``
(B) a gluten-containing grain (including wheat,
barley, rye, and their crossbred hybrids); and
``
(3) whose label fails--
``
(A) to state that the drug contains such an
ingredient; and
``
(B) to identify each such ingredient and, as
applicable, the type of gluten-containing grain.''.
(b) Applicability.--
following:
``
(hh) If it is a drug--
``
(1) that is intended for human use;
``
(2) that contains an ingredient that is, or is derived
directly or indirectly from--
``
(A) a major food allergen; or
``
(B) a gluten-containing grain (including wheat,
barley, rye, and their crossbred hybrids); and
``
(3) whose label fails--
``
(A) to state that the drug contains such an
ingredient; and
``
(B) to identify each such ingredient and, as
applicable, the type of gluten-containing grain.''.
(b) Applicability.--
Section 502
(hh) of the Federal Food, Drug, and
Cosmetic Act, as added by subsection
(a) , shall apply beginning on the
earlier of--
(1) a date to be determined by the Secretary of Health and
Human Services; or
(2) the date that is 2 years after the date of the
enactment of this Act.
(hh) of the Federal Food, Drug, and
Cosmetic Act, as added by subsection
(a) , shall apply beginning on the
earlier of--
(1) a date to be determined by the Secretary of Health and
Human Services; or
(2) the date that is 2 years after the date of the
enactment of this Act.
<all>